Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pediatrix Medical GroupFRA:PDC 54 3-Year EPS without NRI Growth Rate is 7.10% as of Jun. 2026, which is 43% below its 10-year median of 12.50. GuruFocus rates FRA:PDC with a GF Score™ of 54/100 and a GF Value™ of €11.56. The stock has 7 warning signs investors should review. Among 503 Healthcare Providers & Services companies, Pediatrix Medical Group ranks worse than 55.86% on this metric.
During the past 12 months, Pediatrix Medical Group's average EPS without NRI Growth Rate was 23.80% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 7.10% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 9.90% per year.
During the past 10 years, the average EPS without NRI Growth Rate was -8.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Pediatrix Medical Group was 101.80% per year. The lowest was -32.40% per year. And the median was 12.50% per year.
Pediatrix Medical Group (FRA:PDC) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Pediatrix Medical Group 3-Year EPS without NRI Growth Rate Related Terms
FRA:PDC vs ADUS, GRDN, ASTH: 3-Year EPS without NRI Growth Rate Comparison
For the Medical Care Facilities subindustry, Pediatrix Medical Group's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pediatrix Medical Group 3-Year EPS without NRI Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pediatrix Medical Group's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Pediatrix Medical Group's 3-Year EPS without NRI Growth Rate falls into.
Pediatrix Medical Group 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 7.10% mean?
Pediatrix Medical Group (FRA:PDC) has a 3-Year EPS without NRI Growth Rate of 7.10% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Pediatrix Medical Group and its competitors. This is 43% below median its historical median of 12.50. According to the industry distribution chart, Pediatrix Medical Group ranks #281 out of 503 companies in the Healthcare Providers & Services industry, placing it in the top 55.9%.
Is Pediatrix Medical Group's 3-Year EPS without NRI Growth Rate too high?
Pediatrix Medical Group's current 3-Year EPS without NRI Growth Rate of 7.10% is 43% below median its 10-year median of 12.50. The Healthcare Providers & Services industry median 3-Year EPS without NRI Growth Rate is 10.80. Pediatrix Medical Group's value of 7.10% is 34.3% below this industry median. Based on the distribution chart, Pediatrix Medical Group ranks #281 out of 503 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Pediatrix Medical Group has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Pediatrix Medical Group's 3-Year EPS without NRI Growth Rate compare to ADUS and GRDN?
According to the Healthcare Providers & Services industry distribution chart, Pediatrix Medical Group ranks #281 out of 503 companies for 3-Year EPS without NRI Growth Rate. This places Pediatrix Medical Group in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 10.80. Pediatrix Medical Group's value of 7.10% is 34.3% below this benchmark. While the company's 10-year median is 12.50 vs. the industry median of 10.80, Pediatrix Medical Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EPS without NRI Growth Rate among Healthcare Providers & Services companies is 10.80, based on 503 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pediatrix Medical Group's current 3-Year EPS without NRI Growth Rate of 7.10% is 34.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Pediatrix Medical Group and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EPS without NRI Growth Rate is 10.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pediatrix Medical Group's current 3-Year EPS without NRI Growth Rate is 7.10%, which is 43% below median its own 10-year median of 12.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pediatrix Medical Group stock overvalued right now?
Pediatrix Medical Group (FRA:PDC) has a current 3-Year EPS without NRI Growth Rate of 7.10%. The stock's GF Value™ is €11.56, compared to a current price of €22.80 — trading 97.2% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 7.10%, which is 43% below median its 10-year median of 12.50 and 34.3% below the Healthcare Providers & Services industry median of 10.80. Pediatrix Medical Group's overall GF Score™ is 54/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Pediatrix Medical Group (FRA:PDC), the current 3-Year EPS without NRI Growth Rate is 7.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pediatrix Medical Group (FRA:PDC) Overvalued in 2026?
Based on GuruFocus' analysis, Pediatrix Medical Group stock appears to be overvalued.
The current stock price of €22.80 is trading 97.2% above its estimated GF Value™ of €11.56.
Key valuation signals for FRA:PDC:
3-Year EPS without NRI Growth Rate: 7.10% (43% below median its 10-year median of 12.50)
GF Value™: €11.56 vs. price of €22.80 (97.2% above fair value)
Industry Position: 34.3% below the Healthcare Providers & Services median (#281 of 503)
No single metric tells the full story. See the FRA:PDC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
54GF Score
Get the complete analysis for FRA:PDC
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PDC has been successfully added to your 
